Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 21 October 2024 AM
Starpharma has thrown in the towel on registering its broad-spectrum antiviral nasal spray Viraleze on the ARTG.
The pharma has been seeking registration for three years, since the spray was shown to have efficacy against Covid. Rather than any concern about safety or effectiveness, in 2022 the SMH reported the sticking point was the TGA believing the nasal spray should be registered as a medicine, while Starpharma insisted it should be as a medical device.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.